Last reviewed · How we verify
hCD19.IL15.CAR-iNKT
At a glance
| Generic name | hCD19.IL15.CAR-iNKT |
|---|---|
| Sponsor | Kai Lin Xu; Jun Nian Zheng |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hCD19.IL15.CAR-iNKT CI brief — competitive landscape report
- hCD19.IL15.CAR-iNKT updates RSS · CI watch RSS
- Kai Lin Xu; Jun Nian Zheng portfolio CI